In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly reported strong earnings for the second quarter, beating on the top and bottom lines. Disappointing trial results ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...